While the government's proposal to mandate registration for manufacturers and suppliers of printed pharmaceutical packaging materials aims to combat counterfeit drugs, there are significant concerns regarding its practical implementation. The packaging industry, which has not traditionally been under direct regulatory oversight, may find the new requirements complex and potentially burdensome.
The initiative seeks to close existing regulatory gaps by bringing packaging manufacturers and suppliers under formal oversight. However, the lack of a dedicated registration or licensing mechanism under the Drugs and Cosmetics Act, 1940, and its associated Rules, means that the proposed framework introduces a new layer of bureaucracy for an industry that has operated with relative autonomy. This shift could lead to increased operational costs and administrative burdens for packaging entities, potentially affecting their efficiency and profitability.
Moreover, there is concern that illegal operations operating outside the formal framework could continue to bypass licensing requirements, potentially undermining the effectiveness of the proposed regulations. Counterfeiters often adapt quickly to regulatory changes, and without robust enforcement mechanisms, the new registration system may not fully prevent the diversion and misuse of genuine packaging materials.
Additionally, the proposal's focus on registration may not address the root causes of counterfeit drug proliferation, such as inadequate enforcement of existing laws, lack of consumer awareness, and insufficient international cooperation. A more comprehensive approach that includes strengthening enforcement, enhancing public education, and fostering global collaboration may be more effective in tackling the complex issue of counterfeit medicines.